Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2953–2976 of 22,020 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Adult T-cell Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma, T-cell Prolymphocytic Leukemia
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Positron emission tomography-computed tomography, Ruxolitinib; Procedure · Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Columbus, Ohio • Houston, Texas

Conditions: Caregivers, Dementia, Depression
Interventions: WeACT; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Infections
Interventions: Dasatinib, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Cleveland, Ohio • Seattle, Washington

Conditions: Exocrine Pancreatic Insuficiency
Interventions: Fecal Fat; Diagnostic Test
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 7 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • New York, New York + 6 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo, Pridopidine; Drug
Lead sponsor: Prilenia; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 18
States / cities: Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Hemophilia
Interventions: Antithrombin concentrate (ATIIIC), Clotting factor concentrates (CFC) or bypassing agents (BPA), Fitusiran; Biological · Drug
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 11 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • Torrance, California + 4 more

Conditions: Diabetic Kidney Disease (DKD)
Interventions: ALN-ANG3, Evinacumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 59
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more

Conditions: HCC, Intrahepatic Cholangiocarcinoma, Liver Cancer, Liver Metastases
Interventions: MRI-guided adaptive stereotactic ablative body radiotherapy (SABR); Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Alcohol Abuse, Alcohol Abuse/Dependence, Alcohol Addiction, Alcohol Dependence, Alcohol Use Disorder, Alcoholism
Interventions: Deep TMS (DTMS), Sham (No Treatment); Device
Lead sponsor: Brainsway; Industry
Eligibility: 18 Years to 86 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Tuscaloosa, Alabama • La Jolla, California • West Palm Beach, Florida + 6 more

Conditions: Invasive Mould Infection
Interventions: Active Comparator- IV Antifungal (LAmB or voriconazole), EL219; Drug
Lead sponsor: Elion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 11
States / cities: Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more

Conditions: Post-Surgical Pain, Chronic, Post-traumatic Pain, Chronic
Interventions: Peripheral Transcutaneous Magnetic Stimulation from MagVenture; Device
Lead sponsor: Florida International University; Other
Eligibility: 19 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Adolescent Cancer, Cancer, Young Adult Cancer
Interventions: Survey using a questionnaire.; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 15 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Heart Failure (Pediatric), Left Ventricular Systolic Dysfunction
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 18 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 22
States / cities: Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more

Conditions: Lung Carcinoma
Interventions: Best Practice, Educational Intervention, Electronic Health Record Review, Interview, Patient Navigation, Survey Administration; Other · Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Auburn, Washington • Shelton, Washington

Conditions: Healthy
Interventions: Infanrix, Infanrix hexa, Multivalent Group B streptococcus vaccine, Pediarix, Placebo, Prevenar 20, Prevnar 20; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day to 49 Years
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 119
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 54 more

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Atezolizumab, Carboplatin, Etoposide, Lurbinectedin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 12
States / cities: New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more

Conditions: Alpha 1-Antitrypsin, Antibody Deficiency, COPD
Interventions: 20-valent pneumococcal conjugate vaccine; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Solid Tumor Cancer
Interventions: NCCN Distress Thermometer; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: New York, New York • Richmond Hill, New York

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Impulse Dynamics; Industry
Eligibility: 18 Years and older
Enrollment: 5,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 30
States / cities: Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 23 more

Conditions: Ulcerative Colitis
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 12
States / cities: Phoenix, Arizona • San Diego, California • San Francisco, California + 9 more

Conditions: GM1 Gangliosidosis, GM2 Gangliosidosis, Niemann-Pick Type C Disease
Interventions: AZ-3102, Placebo; Drug
Lead sponsor: Azafaros B.V.; Industry
Eligibility: 4 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more

Conditions: Renal Cell Carcinoma
Interventions: Belzutifan, Zanzalintinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: San Francisco, California • Mineola, New York • New York, New York + 3 more

Conditions: Endometrial Cancer
Interventions: Chemotherapy, Trastuzumab Deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 14
States / cities: Fort Lauderdale, Florida • Miami, Florida • Miami Beach, Florida + 10 more

Conditions: Colitis, Colitis, Ulcerative, Inflammatory Bowel Diseases, Ulcerative Colitis
Interventions: Placebo, SPY001, SPY002, SPY003; Other · Drug
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 27
States / cities: Canoga Park, California • La Jolla, California • Lancaster, California + 24 more

Search by objective public record fields.

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

The WeACT Program for Family Caregivers of People Living With Dementia

Dasatinib for HIV-1 Reservoir Reduction

Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment and Reduction of Heavy Drinking in Individuals With of Alcohol Use Disorder (AUD)

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

Uncovering the Mechanism of Pain Relief by Peripheral Transcutaneous Magnetic Stimulation

Comprehensive Care for AYA: Needs Assessment Survey

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer

CCM OPEN HF Registry

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis